Teva Pharmaceutical Industries (WBO:TEVA) Additional Paid-In Capital : €25,572 Mil(As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Teva Pharmaceutical Industries Additional Paid-In Capital?

Teva Pharmaceutical Industries's quarterly additional paid-in capital declined from Sep. 2023 (€26,030 Mil) to Dec. 2023 (€25,499 Mil) but then increased from Dec. 2023 (€25,499 Mil) to Mar. 2024 (€25,572 Mil).

Teva Pharmaceutical Industries's annual additional paid-in capital increased from Dec. 2021 (€24,391 Mil) to Dec. 2022 (€26,137 Mil) but then declined from Dec. 2022 (€26,137 Mil) to Dec. 2023 (€25,499 Mil).

Teva Pharmaceutical Industries Additional Paid-In Capital Historical Data

The historical data trend for Teva Pharmaceutical Industries's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Teva Pharmaceutical Industries Additional Paid-In Capital Chart

Teva Pharmaceutical Industries Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

24,580.80

22,558.15

24,391.49

26,137.47

25,499.02

Teva Pharmaceutical Industries Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															25,889.55	25,611.40	26,029.86	25,499.02	25,572.32

Teva Pharmaceutical Industries Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Teva Pharmaceutical Industries Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Teva Pharmaceutical Industries's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Teva Pharmaceutical Industries (WBO:TEVA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Teva Pharmaceutical Industries Ltd (WBO:TEVA) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

TEVJF:USA TEVA:USA TEVA:Mexico TEVA:Israel 0LER:UK TEV:Germany T1EV34:Brazil

Address

124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020

Website

https://www.tevapharm.com

Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the U.S. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a U.S.-based generic and specialty drug distributor.